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Abstract
Background: Vaccination with live attenuated SIV can protect against detectable infection with wild-type virus. We
have investigated whether target cell depletion contributes to the protection observed. Following vaccination with
live attenuated SIV the frequency of intestinal CD4+CCR5+ T cells, an early target of wild-type SIV infection and
destruction, was determined at days 3, 7, 10, 21 and 125 post inoculation.
Results: In naive controls, modest frequencies of intestinal CD4+CCR5+ T cells were predominantly found within
the LPL TTrM-1 and IEL TTrM-2 subsets. At day 3, LPL and IEL CD4+CCR5+ TEM cells were dramatically increased whilst
less differentiated subsets were greatly reduced, consistent with activation-induced maturation. CCR5 expression
remained high at day 7, although there was a shift in subset balance from CD4+CCR5+ TEM to less differentiated
TTrM-2 cells. This increase in intestinal CD4+CCR5+ T cells preceded the peak of SIV RNA plasma loads measured at
day 10. Greater than 65.9% depletion of intestinal CD4+CCR5+ T cells followed at day 10, but overall CD4+ T cell
homeostasis was maintained by increased CD4+CCR5- T cells. At days 21 and 125, high numbers of intestinal CD4+
CCR5- naive TN cells were detected concurrent with greatly increased CD4+CCR5+ LPL TTrM-2 and IEL TEM cells at day
125, yet SIV RNA plasma loads remained low.
Conclusions: This increase in intestinal CD4+CCR5+ T cells, following vaccination with live attenuated SIV, does
not correlate with target cell depletion as a mechanism of protection. Instead, increased intestinal CD4+CCR5+
T cells may correlate with or contribute to the protection conferred by vaccination with live attenuated SIV.
Background
Non-human primates (NHP) challenged with simian
immunodeficiency virus (SIV) or engineered SIV/HIV-1
chimeras (SHIV) have been used as models to evaluate
the efficacy of a wide variety of candidate AIDS vaccine
approaches for more than two decades [1-6]. Amongst
the vaccine strategies evaluated in NHP models, vaccina-
tion with live attenuated SIV/SHIV has proven to be the
most effective at providing broad protective immunity
against a wide range of SIV and SHIV challenges [7-15].
However, concerns regarding the safety of a live attenu-
ated SIV or HIV vaccine have to date limited further
pursuit of this approach as an AIDS vaccine strategy in
the clinic [16-20]. Nevertheless, the potency of this vac-
cine protection has led to further studies in NHP mod-
els to provide information on the mechanisms of
protective immunity that a safe and effective human
vaccine may have to reproduce to be of equal efficacy
[21].
Many groups have attempted to identify robust corre-
lates of protection amongst the adaptive immune
responses elicited by live attenuated SIV vaccines.
Unfortunately a confusing picture has developed, with
different groups reporting either partial, full or no corre-
lation with various measures of adaptive immunity
[22-39]. This confusion may have resulted from the
range of different NHP models used for these studies:
using different vaccines, different challenge viruses and
different species of macaque. However, since the efficacy
of live attenuated vaccines appears to correlate inversely
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any medium, provided the original work is properly cited.with the level of attenuation [40,41] and the most effec-
tive vaccines persist and replicate in the host [42], then
it is possible that innate responses may also contribute
to the vaccine effect [36,37]. This would appear to be
the case with live attenuated vaccines that have been
reported to protect within as little as 3 weeks vaccina-
tion when adaptive antiviral immune responses are low
or absent [43].
The gut-associated lymphoid tissue (GALT) constitu-
tes a large immune compartment within the body
[44-47] which, compared to other lymphoid compart-
ments, is rich in CD4+ T cells expressing CCR5 [48-50],
a preferential co-receptor for HIV and SIV infection
[51-53]. Early depletion of intestinal CD4+CCR5+
T cells is now a recognised hallmark of wild-type SIV/
HIV infection resulting from the destruction of virus
infected target cells [46,48,54-57]. It could be hypothe-
sised that if live attenuated SIV vaccines caused a simi-
lar loss of CD4+CCR5+ T cells in this compartment,
then this depletion of target cells could contribute to
the vaccine effect. However, it has been reported that
vaccination of rhesus macaques with live attenuated SIV
does not cause significant loss of intestinal CD4+ T cells
[48,58]. Moreover, it has recently been reported that
vaccination with attenuated SIV causes a transient
increase in activated CD4+ memory T cells [58]. None-
theless, dynamic changes in CCR5 expression within
intestinal CD4+ T cell memory subsets were not
assessed in detail, nor have these types of studies been
performed in models involving cynomolgus macaques.
In the present study, we have characterised the impact
on CD4+CCR5+ intestinal T cell memory subsets fol-
lowing inoculation with a potent live nef-attenuated SIV
vaccine in the cynomolgus macaque model. These data
have revealed that vaccination results in dramatic
dynamic changes in key lymphocyte subsets in the
intestinal tract that appear to be more consistent with
immune activation, likely to induce innate and adaptive
responses, than target cell depletion. These changes may
contribute not only to the kinetics of vaccine protection,
but also to the kinetics of virus replication.
Results
Attenuated SIV virus loads in blood and lymphoid tissues
peak at day 10
Following inoculation with live attenuated SIV, plasma
SIV RNA loads (copies/ml) increased significantly at
days 3 and 7 (log10 2.90 ± 0.08, p < 0.001 and log10
4.85 ± 0.14, p < 0.001 respectively) compared to naive
controls, peaking at day 10 (log10 5.54 ± 0.15, p < 0.001;
Figure 1). Compared with day 10, SIV RNA loads
declined significantly by days 14 and 21 (log10 4.57 ±
0.28, p < 0.001 and log10 3.75 ± 0.25, p < 0.001, respec-
tively) onwards to nadir between days 84 and 125 (log10
2.07 ± 0.32 and log10 2.06 ± 0.28, respectively; Figure 1).
Mean levels of <1 SIV DNA copies per 100,000 small
intestine (SI) lymphocytes measured at days 3 and 7
contrasted with peak loads at day 10 (105 ± 85), but
were reduced thereafter at days 21 (21 ± 17) and 125
(2 ± 1). Cell-associated intestinal lymphocytes virus
loads were measured at day 10 (log10 2.25 ± 0.75 SIV
producing cells per 10
6 cells), but declined below detec-
tion limits by day 21 for all intestinal cell samples (data
not shown).
Attenuated SIV does not cause overt depletion of
intestinal CD4+ T cells
Following vaccination with live attenuated SIV, no sig-
nificant change in the total percentage of CD4+ T cells
in peripheral blood mononuclear cells (PBMC), periph-
eral lymph node cells (PLN), mesenteric lymph node
cells (MLN) or spleen was observed at days 3, 7, 10, 21
and 125 compared with naïve controls (Figure 2a). It
was noted that percentages of CD4+ T cells in periph-
eral blood fluctuated following vaccination with live
attenuated SIV but remained within normal reference
range (Figure 2a). Detailed analysis of intra-epithelial
lymphocytes (IEL) and lamina propria lymphocytes
(LPL) from both the SI and large intestine (LI) did not
reveal any significant changes in the total percentage of
CD4+ T cells following vaccination with live attenuated
SIV. A trend towards an increase in the percentage of
CD4+ T cells over time was noted (Figure 2b). However,
this trend was not significant.
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Figure 1 Viral RNA dynamics in macaques vaccinated with
attenuated SIV. Following vaccination of cynomolgus macaques
(n = 20) with live attenuated SIV plasma and lymphoid tissue viral
loads was determined at days 0, 3, 7, 10, 21 and 125 post
inoculation. Mean attenuated SIV RNA plasma levels peaked at day
10 with a nadir between days 84 and 125. For analysis n = 16 at
day 3 reducing to n = 6 by day 21 as animals were sacrificed, n = 2
at all time points thereafter. Error bars shown are ± 1 SEM.
Li et al. Retrovirology 2011, 8:8
http://www.retrovirology.com/content/8/1/8
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CD4+CCR5+ T cells
Analysis of CCR5 expression by CD4+ T cells focused on
memory subsets since naive cells were predominantly
CCR5 negative. No significant changes in the proportion
of CD4+CCR5+ memory T cells within PBMC, PLN,
MLN or spleen were observed following vaccination with
live attenuated SIV (Figure 3a). By contrast, vaccination
with live attenuated SIV resulted in a marked increase in
the mean frequency of all 4 subpopulations of intestinal
CD4+CCR5+ memory T cells taken together at days 3
(40.54% ± 6.24%, p <0.05) and 7 (40.54% ± 7.01%, p
<0.05) compared with naive controls. The mean level of
intestinal CD4+ T cells positive for CCR5 expression in
naive controls was 16.20% ± 2.44%. Remarkably, at day
10 the frequency of intestinal CD4+CCR5+ memory
T cells returned to levels observed in naive macaques
(16.45% ± 3.71%, p = 0.9), apparently wiping out the ear-
lier post vaccination expansion. At day 21, a small
increase in intestinal CD4+CCR5+ memory T cells
(22.50% ± 2.76%, p = 0.16) was not significant. However,
the frequency of this cell population increased signifi-
cantly at day 125 (47.46% ± 5.51%, p < 0.05), with the
caveat that n = 2 at this time point. More detailed analy-
sis of increased intestinal CD4+CCR5+ memory T cells
at days 3, 7 and 125 revealed that these changes occurred
in both the IEL and LPL of the SI and LI (Figure 3b).
Representative dot plots showing CCR5 staining of CD4+
PBMC and SI lymphocytes at each time point are shown
in Figures 3c and 3d, respectively.
Immunohistochemical analysis of CCR5 expression by
LPL within SI sections of macaques vaccinated with
attenuated SIV coincided with the early expansion of
intestinal CD4+CCR5+ T cells seen by flow cytometry
at the same time (data not shown). At day 10, a low fre-
quency of CCR5+ LPL was observed by immunohisto-
chemistry (Figure 4) which coincided with flow
cytometry data showing depletion of intestinal CD4
+CCR5+ T cells at that time. By immunohistochemistry
the level of CCR5+ LPL at day 10 was similar to that of
naive macaques (data not shown). In contrast, at day
125 the proportion of CCR5+ LPL revealed by immuno-
histochemistry was greatly increased (Figure 4), coincid-
ing with expansion of intestinal CD4+CCR5+ T cells
seen by flow cytometry at that time point.
Attenuated SIV upregulates intestinal CD4+ TCM and TEM
cell CCR5 expression
As in man, macaque CD4+ T cell populations can be sub-
divided into three distinct subpopulations: Naive (TN)
which are quiescent and non-dividing, central memory
(TCM) and effector memory (TEM) which are distinguished
by the absence or presence of immediate effector function,
respectively [59]. In cynomolgus macaques these CD4+
T cell subpopulations can be distinguished using a combi-
nation of anti-CD28 and anti-CD95 antibody markers
[59,60]. Using these we found the intestinal CD4+T cells
of naive cynomolgus macaques were almost entirely com-
posed of CD95+CD28+ TCM and CD95+CD28- TEM
memory cells, with relatively few, approximately 1%,
CD95-CD28+ naive (TN) cells present (Figures 5a and 5c:
day 0). Expression of CCR5 was confined primarily to a
small fraction of CD4+ TCM cells, the TEM subset being
largely CCR5- (Figures 5b and 5c: day 0). Following
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Figure 2 CD4+ T cell dynamics in macaques vaccinated with
attenuated SIV. Following vaccination of cynomolgus macaques
(n = 20) with live attenuated SIV peripheral blood, lymphoid tissue
and intestinal lymphocyte CD4+ T cell percentages was determined
at days 0, 3, 7, 10, 21 and 125 post inoculation. No evidence of
overt CD4+ T cell depletion was detected in peripheral blood,
lymphoid tissues (a), or intestinal lamina propria and intraepithelial
lymphocytes of the small and large intestine (b). The mean range of
CD4+ T cell percentages in peripheral blood derived from 335 naïve
cynomolgus macaques ± 2 standard deviations is 35.9% ± 14.52,
shown as a pair of black dashed lines. For analysis of peripheral
blood n = 16 at day 3 reducing to n = 6 by day 21 as animals were
sacrificed, n = 2 at all time points thereafter. For analysis of tissues
n = 4 at all time points except days 7 and 125 where n = 2. Error
bars shown are ± 1 SEM. PBMC: peripheral blood mononuclear cells,
PLN: peripheral lymph node, MLN: mesenteric lymph node, SI: small
intestine, LI: large intestine, IEL: intraepithelial lymphocytes, LPL:
lamina propria lymphocytes.
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Page 3 of 12vaccination with live attenuated SIV, CCR5 expression was
upregulated dramatically in both intestinal CD4+ TCM and
TEM cells at days 3 (20.23% TCM ±1 . 8 4 % ,p<0 . 0 5a n d
23.03% TEM ± 8.13%, p < 0.05) and 7 (23.96% TCM ±
1.99%, p = 0.06 and 16.25% TEM ± 6.09%, p = 0.08; Figures
5b and 5c). However, by day 10 CD4+CCR5+ TCM and
TEM cells were reduced significantly compared with day 7
(11.74% TCM ± 1.18%, p = 0.08 and 4.28% TEM ± 1.13%,
p = 0.08), the remaining intestinal CD4+ T cells being pre-
dominantly CCR5- TCM cells due to marked depletion of
TEM cells (Figures 5b and 5c). At day 21, a significant
increase in the number of intestinal CD4+CCR5- TN cells
compared with naive controls was observed (30.9% ±
9.3%, p = 0.02; Figures 5a and 5c). Concurrently,
restoration of a clearly distinguishable population of CD4+
CD95+CD28- TEM cells was observed (Figure 5c). At day
125 elevated numbers of intestinal TN remained (24.9% ±
3.1%, p = 0.06), but the proportion of CD4+CCR5+ T cells
was now significantly increased, compared to naive con-
trols, (47.46% ± 5.51%, p < 0.05) and the CD4+ TEM subset
was further restored by mostly CCR5+ cells (Figures 5b
and 5c).
Attenuated SIV differentially modulates intestinal LPL and
IEL CD4+ T cells
Using the differentiation sequence defined for rhesus
macaque CD4+ memory T cells where CCR7 and then
CD28 are sequentially down regulated [58,59], it is
Day 3
Day 10 Day 21
Day 0 Day 7
Day 
125
CD4
C
C
R
5
SI Lymphocytes  (d)
(c) PBMC CCR5- CCR5+  
Day 0 Day 3 Day 7
Day 10 Day 21 Day 125
6.7% 57.1% 52.8%
2.8% 8.8% 57.5%
10.7% 10.6% 13.1%
11.1% 9.4% 10.6%
(a)
(b)
SIVmacC8
SIVmacC8
Lymphoid CD4+CCR5+ T Cell Dynamics
Intestinal CD4+CCR5+ T Cell Dynamics
0 7 14 21
0
20
40
60
80
100
75 125
Spleen
PBMC
PLN
MLN
Time (days )
C
D
4
+
C
C
R
5
+
 
m
e
m
o
r
y
 
T
 
c
e
l
l
s
 
(
%
)
0 7 14 21
0
20
40
60
80
100
75 125
SI-IEL
SI-LPL
LI-IEL
LI-LPL
Time (days )
C
D
4
+
C
C
R
5
+
 
m
e
m
o
r
y
 
T
 
c
e
l
l
s
 
(
%
)
Figure 3 CCR5+ T cell dynamics in macaques vaccinated with attenuated SIV. Following vaccination of cynomolgus macaques (n = 20)
with live attenuated SIV peripheral blood, lymphoid tissue and intestinal lymphocyte CD4+CCR5+ memory T cell percentages was determined at
days 0, 3, 7, 10, 21 and 125 post inoculation. There was no evidence of dynamic changes in percentages of CD4+CCR5+ memory T cell in
peripheral blood and lymphoid tissues (a). In contrast, dynamic changes in CD4+CCR5+ memory T cell percentages was observed in the lamina
propria and intraepithelial lymphocytes of both the small and large intestine (b). Panels (c) and (d) shows representative staining for CCR5 on
CD4+ PBMC and SI lymphocytes, respectively, at each time point. CCR5+CD4+ T cells are shown in red and CCR5-CD4+ T cells in green. For
analysis of peripheral blood n = 16 at day 3 reducing to n = 6 by day 21 as animals were sacrificed, n = 2 at all time points thereafter. For
analysis of tissues n = 4 at all time points except days 7 and 125 where n = 2. Error bars shown are ± 1 SEM. PBMC: peripheral blood
mononuclear cells, PLN: peripheral lymph node, MLN: mesenteric lymph node, SI: small intestine, LI: large intestine, IEL: intraepithelial
lymphocytes, LPL: lamina propria lymphocytes.
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memory T cells into 4 subsets, CD28+CCR7+ TCM ®
CD28+CCR7+ TTrM-1 ® CD28+CCR7- TTrM-2 ®
CD28-CCR7- TEM, where the transitional memory sub-
set-1 (TTrM-1) are essentially CCR5+ TCM cells. Using
this regimen, we investigated further CCR5 expression
by intestinal LPL and IEL CD4+ memory T cells follow-
ing vaccination with live attenuated SIV. Rather than
TCM cells, defined previously as CD28+ cells, we found
that the majority of intestinal CD4+ memory T cells in
naive cynomolgus macaques were in fact of the transi-
tional memory subset-2 (TTrM-2) and negative for CCR5
expression (Figures 6a, b and 6c). Representative dot
plots showing CCR5 staining of SI LPL and IEL CD4+
memory subsets are shown in Figure 6c. Modest fre-
quencies of CCR5+ cells were mostly found in the
TTrM-1 subset of LPL and the TTrM-2 subset of IEL of
naive macaques (Figures 6b and 6c). At day 3, there was
a dramatic increase in CCR5 expression by both CD4+
TEM and TTrM-2 cells accompanied by a large population
shift to a TEM cell phenotype, in both LPL and IEL (Fig-
ures 6b and 6c). At the same time CD4+ TCM and
TTrM-1 cells were depleted within LPL and IEL popula-
tions (Figures 6a and 6c). At day 7, the majority of LPL
and IEL CD4+ TEM cells appeared to have either
reverted to a TTrM-2 cell phenotype or were depleted,
whilst the remaining CD4+ TTrM-2 cells were largely
positive for CCR5 expression (Figures 6b and 6c). Very
few LPL and IEL CD4+ TCM and TTrM-1 cells were
detected at day 7 and at all time points investigated
thereafter (Figures 6a and 6c). At day 10, CCR5 expres-
sion within the CD4+ TEM and TTrM-2 subsets, within
LPL and IEL, was almost completely lost (Figures 6b
and 6c). The remaining LPL and IEL CD4+ TEM and
TTrM-2 cells were largely negative for CCR5 expression
(Figures 6b and 6c). At day 21, a higher frequency of
IEL CD4+CCR5+ TEM cells was observed, but no
marked increase was seen in the frequency of LPL CD4+
C C R 5 +Tc e l l s( F i g u r e s6 ba n d6 c ) .A td a y1 2 5 ,t h e
proportion of IEL CD4+CCR5+ TEM cells increased further
although TTrM-2 cells were largely CCR5- (Figures 6b
and 6c). By contrast, the frequency of LPL CD4+ TEM cells
was greatly reduced and TTrM-2 cells increased at day
125 (Figure 6a). Marked increases in the frequency of LPL
CD4+CCR5+ cells at day 125 were mostly confined to the
TTrM-2 subset (Figures 6b and 6c), further distinguishing it
from the IEL compartment at this time.
Discussion
Live attenuated SIV vaccines provide potent protection,
but the detailed properties of this protection appear to
vary depending upon the model system studied. In this
report, we describe further studies to characterise the
mechanism of protection conferred by a minimally nef-
deleted attenuated vaccine derived from SIVmac251,
called SIVmacC8 [61], in (Mauritian derived) cynomol-
gus macaques. Vaccination of cynomolgus macaques
with SIVmacC8 protects against infection with virus
infected cells as well as cell free virus [5], develop by
3 weeks [43] and paradoxically protects against a
Control Day 10 Day 125
Figure 4 Representative immunohistochemistry showing expression of CCR5 by lamina propria lymphocytes in the small intestine of
macaques vaccinated with attenuated SIV. Following vaccination of cynomolgus macaques (n = 20) with attenuated SIV
immunohistochemical staining for CCR5+ cells was performed on sections of small intestine. At day 10 (left panel) a low frequency of CCR5+
cells (brown cell surface staining) was observed in the T cell areas of the lamina propria surrounding crypts (delineated by a dashed red line in
each panel). In contrast, at day 125 (centre panel) a high frequency of CCR5+ cells was seen in the T cell areas of the lamina propria. The right
hand panel shows a control slide with anti-CCR5 antibody omitted. Sections shown are from representative animals, counterstained with
haematoxylin. Magnification is ×100.
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Page 5 of 12genetically heterologous virus challenge better (N. Berry
personal communication) than a highly vigorous homo-
l o g o u sv i r u sc h a l l e n g e[ 3 7 ] .S i n c ew eh a v eb e e nu n a b l e
to identify a mechanism of protection amongst adaptive
immune responses that develop following vaccination,
either by passive transfer of immune serum [24] or CD8
+ T cell depletion [34,62], we investigated whether other
responses to vaccination may contribute to protection. It
is accepted that infection with wild-type SIV rapidly
induces a depletion of CD4+CCR5+ memory T cells in
the GALT [54-57]. Therefore, we speculated whether a
similar effect following vaccination with SIVmacC8
w o u l dr e s u l ti nt a r g e tc e l ld e p l e t i o n ,p r e v e n t i n g
subsequent virus challenges from infecting the GALT
and so preventing a systemic infection from being estab-
lished. The data indicate that, following inoculation of
SIVmacC8, marked dynamic changes in CD4+ T cell
populations occur that may not only contribute to the
protective effect of vaccination, but could also be instru-
mental in regulating the kinetics of replication by this
virus.
Previous reports of T cell dynamics in the GALT of
rhesus macaques, following infection with attenuated
SIV, suggested that minimal changes occurred since the
total CD4+population remained unaltered [48,58]. This
also appeared to be the case for cynomolgus macaques
vaccinated with SIVmacC8. However, more detailed
analyses of CD4+CCR5+ memory T cell populations
revealed a more dynamic picture of events.
By immunostaining with antibodies to CD3, CD4,
CCR5, CD28, CD95 and CCR7 markers, it was possible
to define the naive and memory helper T cell compart-
ments in considerable detail. Prior to vaccination with
SIVmacC8, the low level of CCR5 expression by CD4+
TEM cells in naive cynomolgus macaques would be
anticipated with a lack of activation and proinflamma-
tory Th1 responses [63-65]. By contrast, within 3 days
of vaccination when the primary viraemia is first detect-
able, a dramatic expansion of intestinal CD4+CCR5+
TEM cells was detected, consistent with an acute Th1
proinflammatory response [66-68]. This expansion of
intestinal CD4+CCR5+ TEM cells was probably a result of
activation-associated upregulation of CCR5 expression by
CD4+CCR5- T cells, since concurrent reductions in less
differentiated CD4+ TCM,T TrM-1 and TTrM-2 cells were
detected. Alternative explanations such as the prolifera-
tion of intestinal CD4+CCR5+ TEM cells or an influx of
CD4+CCR5+ TEM cells into the intestinal mucosa are
less likely because of the limited proliferative potential of
TEM cells [69] or the need for co-ordinated outflow of
CD4+CCR5- T cells to balance overall CD4+ T cell
percentages.
The marked expansion in the activated intestinal CD4+
CCR5+ cell population in the absence of acquired
immune responses would provide large numbers of target
cells in which SIVmacC8 could replicate readily. Indeed,
virus infected cells are detectable in the small intestine
from day 3 by immunohistochemistry (D. Ferguson per-
sonal communication). However, it is not known whether
this series of events reflects SIV exploiting a generic host
response to infection or whether it is a result of specific
viral factors driving events. Nevertheless, not only did the
early expansion of intestinal CD4+CCR5+ T cells, detect-
able from day 3, appear to “fuel” the increases in plasma
SIV RNA loads at days 3 and 7, but also the loss of LPL
and IEL CD4+CCR5+ TEM cells from day 7 also augured
the end of the primary viraemia from day 10 when there
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Figure 5 CD4+CCR5+ TCM and TEM cell dynamics in the small
intestine of macaques vaccinated with attenuated SIV.
Following vaccination of cynomolgus macaques (n = 20) with live
attenuated SIV the percentages of CD4+CCR5+ TCM and TEM cells
from the SI was determined at days 0, 3, 7, 10, 21 and 125 post
inoculation. Dynamic changes in the frequency of SI CD4+
lymphocytes naïve, TCM,T EM subsets was observed following
vaccination (a). Increases in the percentage of CD4+CCR5+ TCM and
TEM cells was observed at days 3 and 7, reversed at days 10 and 21,
then increased again at day 125 compared to naive controls (b).
Immunostaining of SI lymphocytes gated on CD3+CD4+ T cells
from one representative animal from each time point are shown (c).
In each panel the left hand quadrant shows CD28+CD95- TN cells,
the upper right quadrant CD28+CD95+ TCM cells and the lower
right quadrant CD28-CD95+ TEM cells. Percentages shown give the
proportion present in each of these subsets. CD4+CCR5+ T cells are
shown in red and CD4+CCR5- T cells in green. TN: naive, TCM:
central memory, TEM: effector memory, SI: small intestine.
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Page 6 of 12were dramatic reductions in remaining LPL and IEL CD4
+CCR5+ TTrM-2 cells to pre-infection levels. These data,
which were virtually indistinguishable from those pre-
viously reported for this virus [70], suggest that the
kinetics of SIVmacC8 primary viraemia may be regulated
by the availability of target cells as much as the develop-
ment of anti-viral immune responses. Studies of the
infection of Chinese rhesus macaques with pathogenic
SIV have also reported that peak plasma SIV RNA loads
were associated with the loss of intestinal CD4+CCR5+
T cells [71,72]. Nevertheless there is considerable evi-
dence that acquired anti-SIV immune responses, such as
CD8+ cytotoxic T cells, regulate viral loads [33,34,73-76].
Intriguingly, in a previous report of the primary viraemia
of SIVmacC8 during profound CD8+ cell depletion,
whilst the peak SIV RNA loads were approximately 300
times higher in the absence of CD8+ T cells, SIV RNA
loads declined prior to recovery of detectable CD8+ T
cells [34], indicating that other mechanisms must also
contribute to the control of the primary viraemia.
The dramatic loss of intestinal CD4+CCR5+ T cells
between days 7 and 10, post vaccination with attenuated
SIV, may be due to indirect mechanisms such as CD95
dependant apoptosis [56] as well as direct lytic viral
replication. However, it is unclear why overall CD4+
T cell percentages were not then reduced, as per wild-
type SIV infection [48,58]. It may be that lower cell-
associated virus loads and the non-pathogenic nature of
attenuated SIV infection reduce rates of CD4+CCR5+
T cell attrition thereby allowing T cell homeostatic
repopulation of the GALT to be sustained. Such repo-
pulation could originate from outside the GALT or
through expansion of intestinal CD4+CCR5- TEM and
TTrM-2 cell populations. Though at this time there were
few naive TN cells detectable to suggest repopulation,
and TEM cells have been reported to have limited prolif-
erative capacity [77,78]; however, the high proliferative
capacity of CD4+ TTrM-2 [59] cells could have been able
to support that repopulation. Alternatively, down regula-
tion of CCR5 expression on CD4+CCR5+ T cells may
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Figure 6 Vaccination with attenuated SIV differentially modulates LPL and IEL CD4+CCR5+ T cell memory subsets.F o l l o w i n g
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between days 7 and 10, that is not necessarily due to
depletion. In order to address this possibility we need to
investigate whether CD4+CCR5- cells harbour attenu-
ated SIV, as others have found with pathogenic SIV [57].
Nevertheless, at days 21 and 125, there was a dramatic
increase in intestinal TN cells that may signify an influx
of repopulating cells to replace ongoing losses and
maintain homeostasis, as has been reported following
infection with pathogenic SIV [48]. Since the second
dramatic increase in CD4+CCR5+ intestinal T cells at
day 125 occurred without the appearance of increased
SIV RNA loads, other factors not present during the
acute infection must be restricting SIV replication, pre-
venting further loss of intestinal CD4+CCR5+ T cells.
Further work is needed to determine whether adaptive
immune or other anti-viral responses, such as retroviral
superinfection resistance, are involved at these later
times specifically [79]. Whatever the mechanism identi-
fied, it needs to be able to account for the characterised
properties of protection conferred by live attenuated
vaccines in the species of macaque being studied.
One of the difficulties for understanding vaccine pro-
tection conferred by live attenuated SIV has been the fre-
quently confusing, if not conflicting data, obtained by
different groups using related vaccine models but in
different species of macaque. In this report, we found
a much lower frequencies of intestinal CD4+CCR5+ T
cells (16.16% ± 2.44%) in naive cynomolgus macaques
compared with Indian rhesus macaques, where the
level of CCR5 expression by CD4+ intestinal T cells is
reported to be >60% [57]. Intriguingly, average levels
of CCR5 expression on CD4+ intestinal T cells of SIV
natural hosts is reported to be considerably lower
those we have described. For example, 9.13% for Afri-
can green monkeys and 1.2% for sooty mangabeys
[80]. It may be hypothesised that this lower level of
CCR5 expression by CD4+ T cells may contribute to
t h em o r el i m i t e dd a m a g eo ft h ei m m u n es y s t e m
caused by wild-type SIV in these hosts as there would
be reduced numbers of target cells susceptible to
infection and destruction at any time [80]. Conversely,
the higher levels of CCR5 expression on peripheral
CD4+ T cells of Indian versus Chinese rhesus maca-
ques, 21.8% ± 7.7% and 6.7% ± 4.6% respectively,
could contribute to the sustained high virus load and
faster disease progression seen in Indian rhesus maca-
ques infected with SIV [72,81]. If alterations in the
frequency of these same CD4+ T cell subsets contri-
bute not only to viral kinetics but also to the protec-
tion mediated by live attenuated SIV, then it may be
anticipated that undertaking a similar vaccine study in
macaques of different species could result in distinct
outcomes.
Conclusions
Vaccination with live attenuated SIV causes dynamic
changes and chronic expansion of CD4+CCR5+ intestinal
T cell memory subsets, more consistent with immune acti-
vation than target cell depletion. The profile of high fre-
quencies of CD4+CCR5+ T cells detectable in the GALT
after vaccination is not identical to those found in naive
animals or expanded during the early stages of the primary
viraemia, implying lasting immune modulation. Under-
standing the impact of the immune modulation caused by
attenuated SIV and the mechanism(s) involved may provide
insight into the development of novel vaccine approaches
or therapies that safely reproduce this protection.
Methods
Experimental Outline
In this study, twenty D-type-retrovirus-free juvenile
cynomolgus macaques (Macaca fascicularis), housed and
maintained in accordance with UK Home Office guide-
lines for the care and maintenance of nonhuman pri-
mates, were used. Animals were sedated with ketamine
hydrochloride before inoculation of virus or venepunc-
ture and killed humanely by an overdose of anaesthetic.
The vaccine virus SIVmacC8 is a clone of a rhesus pas-
sage of wild-type SIVmac251 [8] attenuated by a 12 bp
in-frame deletion in the nef open reading frame and two
further conservative amino acid changes [61]. Cynomol-
gus macaques were inoculated with vaccine virus by
intravenous injection of 5000 TCID50 of the 9/90 pool
of SIVmacC8 [61], which has an end-point titre of 10
4
TCID50/ml on C8166 cells, and were sacrificed in pairs
on days 3, 7, 10, 21 and 125 (n = 2) in the first study
and days 3, 10 and 21 (n = 2) in a second study for ana-
lysis and comparison with naive macaques (n = 4) of
CCR5 expression across CD4+ T cell memory subsets.
Tissue collection
PBMCs were isolated by density gradient centrifugation
as previously described [34]. Spleen, PLN and MLN
cells were isolated by mechanical tissue disaggregation
(Medimachine, BD Biosciences, Oxford, UK). LPL and
I E Lw e r ei s o l a t e df r o mt h eS Ia n dL I .B r i e f l y ,i n t e s t i n a l
sections were opened longitudinally, cut into 5 cm seg-
ments and washed with cold HBSS (Gibco
®Invitrogen
Ltd., Paisley, UK). Segments were then incubated in cold
Ca
2+ and Mg
2+ free HBSS (Gibco
®Invitrogen Ltd., Pais-
ley, UK) containing 10 mM Dithiothreitol (Sigma-
Aldrich, Dorset, UK) on an orbital shaker for 45-60
minutes at 4°C. After incubation IEL were collected as
the filtrate from a 100 μm cell strainer (BD Biosciences,
Oxford, UK). Remaining intestinal tissue was then incu-
bated with warm collagenase solution (0.5 mg/ml) on an
orbital shaker at 37°C for 30-45 minutes. After incuba-
tion LPL were collected as the filtrate from a 100 μm
Li et al. Retrovirology 2011, 8:8
http://www.retrovirology.com/content/8/1/8
Page 8 of 12cell strainer (BD Biosciences, Oxford, UK). All extracted
filtrates were centrifuged at 400 g for 10 min, pellets re-
suspended in RPMI 1640 (Sigma-Aldrich, Dorset, UK),
l a y e r e do n t oF C Sa n ds p u na t4 0 0gf o r1 0m i n .C e l l
pellets were re-suspended in RPMI 1640 containing 2
mg/ml DNAse (Sigma-Aldrich, Dorset, UK) and incu-
bated for 20 min on shaker at 37°C. Cell suspensions
were layered over a 35% Percoll gradient (Sigma-
Aldrich, Dorset, UK) which was layered over a 65%
Percoll gradient and centrifuged at 500 g for 30 min.
Lymphocytes present at the interface between the 35%
and 65% Percoll layers were aspirated and cells washed
twice in RPMI 1640. Prior to staining cells were further
processed using a “Dead Cell Removal Kit”, according to
manufacturer’s instructions, to reduce debris (Miltenyi
Biotec, Surrey, UK).
Detection and quantification of SIV RNA, DNA and cell-
associated virus
SIV RNA levels in plasma were determined by quantita-
tive real-time RT-PCR (qRT-PCR) as previously
described [37]. Viral RNA was extracted from 140 μl
plasma using viral RNA mini-kits (QIAamp; Qiagen,
Crawley, UK) then eluted in a total volume of 50 μlA V E
buffer. RNA (5 μl) extracted from reference or experi-
mental samples were amplified in triplicate using the
Brilliant QRT-PCR plus Core Reagents one-step kit (Agi-
lent Technologies Inc., CA, USA). Oligonucleotide pri-
mers and probe sequences, located in conserved regions
of gag, were optimized at 300 and 100 nM respectively
[37]. A value of 1.3 log10 SIV RNA copies per ml is
below the cut-off for quantification in this assay. Cell-
associated virus loads of isolated lymphoid cells were
determined by co-culture with C8166 cells, and the pre-
sence of replicating virus was confirmed by syncytia iden-
tification or by antigen capture at 28 days [62].
Genomic DNA was extracted from 10
6 purified intest-
inal lymphocytes (as described above) and proviral SIV
gag DNA levels determined by quantitative PCR (qPCR),
using the same primer/probe sequences as the qRT-PCR
assay [37]. The concentration added to each PCR assay
was determined retrospectively using a fluorometic
DNA quantification kit (Sigma-Aldrich, Dorset, UK) in a
microtitre format. Aliquots of DNA (1 μl) were assayed
in triplicate using a Taqman Universal PCR Master Mix
(ABI) against a standard curve of the p2-LTR plasmid
[70] serially diluted in herring sperm DNA [37]. SIV
DNA levels were expressed as copies of SIV DNA per
10
5 mononuclear cells (MNC) with an absolute limit of
detection being 1 SIV DNA copy per 10
5 cells.
Analysis of CCR5 expression by T cell memory subsets
Expression of CCR5 within T cell subsets defined by CD3-
FITC (clone FN18, AbD Serotec, UK), CD4-APC-Cy7
(clone OKT4, Biolegend, Cambridge, UK), CD8-AmCyan
(clone SK1, BD Biosciences, Oxford, UK), CD28-PerCP-
Cy5.5 (clone CD28.2, eBioscience Ltd., Hatfield, UK),
CD95-PE-Cy7 (clone DX2, eBioscience Ltd., Hatfield, UK)
and CCR7-FITC (clone 150503, R&D systems, Abingdon,
UK) was assessed by flow cytometry. Within the CD3+
CD4+ (helper) T cell subset, naive (CD95-CD28+, TN),
central memory (CD95+CD28+ or CD95+CD28+CCR7+
CCR5-, TCM), transitional memory subset-1 (CD95+
CD28+CCR7+CCR5+, TTrM-1), transitional memory sub-
set-2 (CD95+CD28+CCR7-, TTrM-2) and effector memory
(CD95+CD28- or CD95+CD28-CCR7-, TEM) distinctions
were made [59,60]. Staining was performed as previously
described [29]. Acquisition was performed using a BD
FACSCanto II and analysed using BD FACSDiva software
(BD Biosciences, Oxford, UK). At least 10,000 CD3+CD4+
events were collected for subset analysis.
Immunohistochemical analysis was performed as pre-
viously described [82]. Briefly formaldehyde fixed, paraf-
fin embedded tissue sections were de-waxed, and
re-hydrated before being incubated with 50 μg/ml protei-
nase K (Roche Products Ltd., Welwyn Garden City, UK)
in PBS pH7.4 for 15 minutes at 37°C to unmask target
antigens followed by immuno-labelling with anti-CCR5
(3A9, BD Biosciences, Oxford, UK). Bound antibodies
were visualized using the Vector ABC amplification sys-
tem (Vector Laboratories, Peterborough, UK) in combi-
nation with a biotinylated universal anti-mouse/rabbit
secondary antibody (Vector Laboratories, Peterborough,
UK).
Statistical analysis
A Kruskal-Wallis test followed by Dunn’sp o s tt e s tw a s
used for comparison of CD3+CD4+ and CD3+CD4
+CCR5+ counts and plasma SIV vRNA loads at each
time point measured. Values expressed are mean ± stan-
dard error of means (SEM). All reported P values were
two sided at the 0.05 significance level determined using
Prism 5 software (Graph Pad Software, CA, USA).
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